A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|171|4|539-546

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.4, 2015-11, pp. : 539-546

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma

By  

Oncology, Vol. 70, Iss. 6, 2007-02 ,pp. : 411-417

Karger

Access to resources Recommend Favorite

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 365-373

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 7-14

Karger

Access to resources Recommend Favorite